{"id":"pegylated-interferon-and-imatinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":null,"effect":"Gastrointestinal toxicity (nausea, diarrhea)"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Depression/neuropsychiatric effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegylated interferon-alpha activates innate and adaptive immune responses, enhancing natural killer cell and T-cell activity against malignant cells. Imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases, preventing tumor cell growth and inducing apoptosis. The combination aims to synergize immunological and targeted mechanisms.","oneSentence":"This combination uses pegylated interferon to enhance immune response against cancer cells while imatinib inhibits tyrosine kinases to block tumor cell proliferation and survival signaling.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:47:53.628Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML) in phase 3 development"}]},"trialDetails":[{"nctId":"NCT02001818","phase":"PHASE2","title":"Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia","status":"COMPLETED","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2014-04-11","conditions":"Chronic Myeloid Leukaemia","enrollment":60},{"nctId":"NCT00573378","phase":"PHASE2","title":"Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2007-09","conditions":"Chronic Myeloid Leukemia","enrollment":12},{"nctId":"NCT01227356","phase":"PHASE2","title":"A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2004-09","conditions":"Health Care Quality, Health Care Evaluation","enrollment":112},{"nctId":"NCT00297570","phase":"PHASE3","title":"Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2006-02","conditions":"Leukemia, Myeloid, Philadelphia-Positive","enrollment":90},{"nctId":"NCT00511121","phase":"PHASE2","title":"Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)","status":"TERMINATED","sponsor":"University of Bologna","startDate":"2001-04","conditions":"Chronic Myeloid Leukemia","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pegylated Interferon and Imatinib","genericName":"Pegylated Interferon and Imatinib","companyName":"Sheba Medical Center","companyId":"sheba-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses pegylated interferon to enhance immune response against cancer cells while imatinib inhibits tyrosine kinases to block tumor cell proliferation and survival signaling. Used for Chronic myeloid leukemia (CML) in phase 3 development.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}